The Industry of Bodies Donated for Science Lacks Oversight: Investigations

Reuters sheds light on the largely unregulated trade of human body parts taken from human cadavers donated for science.

Written byKatarina Zimmer
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

An anatomy lab WIKIMEDIA, CAMPBELL UNIVERSITYFederal officials found four fetuses among various human remains in a 2013 raid of businessman Arthur Rathburn’s Detroit warehouse, Reuters reported this week (December 26). Rathburn, who formerly sold human tissues, was charged earlier this year for defrauding his customers by sending them infected body parts and will stand for trial in January 2018.

This is the latest in a series of discoveries uncovered by Reuters documenting the unregulated state of the so–called “body broker” industry, which specializes in the trade of human body parts for use in medical research and education. The majority of the 34 body broker businesses across the U.S. that were examined in investigations by the news agency earlier this year are for-profit corporations, some earning several million dollars a year.

“The current state of affairs is a free-for-all,” Angela McArthur, director of the University of Minnesota Medical School’s body donation program tells Reuters. “I don’t know if I can state this strongly enough. . . . What they are doing is profiting from the sale of humans.”

In general, buying and selling human cadavers ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies